The role of PD-1 in exogenous IL-33-driven ILC-2 antitumor responses has been reported in models of pancreatic cancer (25) and in metastatic melanoma (36), but whether PD-1 function is relevant in the absence of the addition of exogenous IL-33 is unknown. This evidence concerns the gene IL33 and metastatic melanoma.